Description of the applicable disease types and treatment scope of Ceritinib/Ceritinib (Zanda)

Ceritinib (Ceritinib, also known as ceritinib) is a second-generation ALK (anaplastic lymphoma Kinase) tyrosine kinase inhibitor, mainly targeted at patients with advanced non-small cell lung cancer (NSCLC) carrying ALK gene rearrangements. Since the discovery of the ALK gene rearrangement, it has become a key driver mutation in some lung cancers, and the emergence of ALK inhibitors has completely changed the treatment landscape for these patients. The development of ceritinib aims to provide a more efficient and broader-spectrum treatment option for patients who are resistant or intolerant to first-generation ALK inhibitors (such as crizotinib).

The core indication of ceritinib is the treatment of patients with ALK-positive locally advanced or metastatic non-small cell lung cancer, including those who have failed first-generation ALK inhibitors such as crizotinib. ALK rearrangement accounts for about 3% to 7% of patients with non-small cell lung cancer, and is more common in young patients who are non-smokers or light smokers. Clinical studies have shown that ceritinib can effectively inhibit the proliferation of ALK positive lung cancer cells and block downstream signaling pathways, such as PI3K/AKT and RAS/RAF/MEK/ERK, thereby inhibiting tumor growth. Compared with the first-generation ALK inhibitors, ceritinib is more widely distributed in the body, can penetrate the blood-brain barrier, and also shows efficacy in patients with brain metastases. This is particularly important for patients with ALK-positive lung cancer who have a higher risk of brain metastases.

In addition to non-small cell lung cancer, ceritinib is being explored in other solid tumors harboring ALK rearrangements or ROS1 mutations. For example, patients with certain rare types of tumors, such as anaplastic large cell lymphoma (ALCL), papillary thyroid carcinoma, and neuroblastoma, may also potentially benefit from ALK gene abnormalities. Although these indications have not yet been fully approved, early clinical trial results show that ceritinib can achieve partial response or disease stabilization in these patients, suggesting that its scope of application may be further expanded.

In clinical practice, the treatment scope of ceritinib also includes patients in different treatment lines: it can be used as first-line treatmentALKpositiveNSCLC patients can also be used as second-line or late-line treatment for patients who are resistant to first-generation ALK inhibitors. Compared with traditional chemotherapy, ceritinib has more significant efficacy, higher objective response rate (ORR), significantly longer progression-free survival (PFS), and relatively controllable toxic and side effects, such as mild to moderate gastrointestinal reactions, abnormal liver function, etc., which can be controlled through dose adjustment and drug management. In addition, ceritinib is particularly important for patients with brain metastases, because the brain is the main site where ALK-positive lung cancer is prone to metastasis, and its good blood-brain barrier permeability makes it a clinical advantage in such patients.

In general, ceritinib is mainly suitable for patients with ALK -positive advanced or metastatic non-small cell lung cancer, including first-line and second-line treatment groups. It also has potential efficacy in other rare ALK or ROS1 related solid tumors. Its broad-spectrum targeting effect, ability to penetrate the blood-brain barrier and its application value in a generation of drug-resistant patients make it an important targeted therapy drug in the context of precision medicine. With the continuous accumulation of clinical research and real-world data, the scope of application of ceritinib in lung cancer and other ALK-driven tumors is expected to be further expanded, bringing opportunities for long-term survival and improved quality of life to more patients.

Reference materials:https://www.drugs.com/